Oruka Therapeutics appoints Todd Edwards as Chief Commercial Officer

Oruka Therapeutics, a clinical-stage biotechnology company focusing on chronic skin diseases such as plaque psoriasis and hidradenitis suppurativa, has appointed Todd Edwards as its new Chief Commercial Officer. Edwards brings over 25 years of experience in immunology and dermatology, having previously held leadership roles at Arcutis Biotherapeutics, Incyte Corporation, and UCB S.A.

In a separate financial update, FactSet reports that analysts have revised the 2026 earnings per share (EPS) median estimate for Oruka Therapeutics upward to -2.2 USD from -2.28 USD. The average target price for the company is set at 151.00 USD.